Total Payments
$1,216
2024 Payments
$41.76
Companies
14
Transactions
76
Medicare Patients
9,716
Medicare Billing
$451,642
Payment Breakdown by Category
Food & Beverage$1,216 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,216 | 76 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $273.94 | 14 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $206.57 | 19 | $0 (2023) |
| PFIZER INC. | $205.45 | 14 | $0 (2022) |
| Merck Sharp & Dohme LLC | $196.16 | 10 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $96.12 | 7 | $0 (2023) |
| Abbott Laboratories | $75.98 | 1 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27.46 | 2 | $0 (2017) |
| Baxter Healthcare | $26.86 | 1 | $0 (2024) |
| Amgen Inc. | $26.41 | 2 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $23.82 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41.76 | 2 | Baxter Healthcare ($26.86) |
| 2023 | $208.87 | 8 | Abbott Laboratories ($75.98) |
| 2022 | $308.11 | 23 | E.R. Squibb & Sons, L.L.C. ($152.59) |
| 2021 | $381.06 | 24 | Merck Sharp & Dohme Corporation ($133.46) |
| 2020 | $13.82 | 1 | AstraZeneca Pharmaceuticals LP ($13.82) |
| 2019 | $38.95 | 3 | Amarin Pharma Inc. ($16.34) |
| 2017 | $223.20 | 15 | Novartis Pharmaceuticals Corporation ($44.35) |
All Payment Transactions
76 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN, TRULANCE | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Gastroenterology | ||||||
| 02/14/2024 | Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 10/16/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/29/2023 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $75.98 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/11/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/14/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/19/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $12.73 | General |
| Category: Cardiovascular | ||||||
| 03/15/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/27/2023 | Merck Sharp & Dohme LLC | BELSOMRA (Drug), VERQUVO, VERQUVO | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: NEUROSCIENCE | ||||||
| 01/09/2023 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/14/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $10.85 | General |
| Category: Cardiovascular | ||||||
| 11/23/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $9.18 | General |
| Category: Cardiovascular | ||||||
| 11/10/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $7.73 | General |
| Category: Cardiovascular | ||||||
| 10/19/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $12.46 | General |
| Category: Cardiovascular | ||||||
| 10/11/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $8.72 | General |
| Category: Cardiovascular | ||||||
| 09/21/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $9.15 | General |
| Category: Cardiovascular | ||||||
| 08/17/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $10.04 | General |
| Category: Cardiovascular | ||||||
| 07/28/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.26 | General |
| Category: Cardiovascular | ||||||
| 07/21/2022 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/08/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.96 | General |
| Category: Cardiovascular | ||||||
| 06/16/2022 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $8.71 | General |
| Category: Cardiovascular | ||||||
| 05/26/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/17/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/02/2022 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/25/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,616 | 1,993 | $355,869 | $81,726 |
| 2022 | 21 | 2,442 | 3,145 | $571,066 | $114,546 |
| 2021 | 23 | 3,033 | 3,852 | $683,735 | $140,639 |
| 2020 | 23 | 2,625 | 3,272 | $658,846 | $114,730 |
Total Patients
9,716
Total Services
12,262
Medicare Billing
$451,642
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 268 | 315 | $87,404 | $25,672 | 29.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 171 | 173 | $61,314 | $8,690 | 14.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 72 | 72 | $34,910 | $8,454 | 24.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 58 | 58 | $43,803 | $7,931 | 18.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 56 | 62 | $24,090 | $7,473 | 31.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 85 | 92 | $18,032 | $5,588 | 31.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 88 | 88 | $21,272 | $4,832 | 22.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $7,080 | $2,018 | 28.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 173 | 178 | $10,911 | $1,678 | 15.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 219 | 272 | $8,288 | $1,562 | 18.8% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 49 | 98 | $9,306 | $1,481 | 15.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 88 | 88 | $7,001 | $1,363 | 19.5% |
| 85610 | Blood test, clotting time | Office | 2023 | 26 | 229 | $3,229 | $961.80 | 29.8% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 88 | 88 | $4,713 | $911.33 | 19.3% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 48 | 50 | $4,378 | $896.21 | 20.5% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Facility | 2023 | 45 | 45 | $3,938 | $804.76 | 20.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 21 | 22 | $2,572 | $714.34 | 27.8% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Facility | 2023 | 22 | 22 | $2,110 | $443.30 | 21.0% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 27 | 29 | $1,518 | $252.84 | 16.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 357 | 487 | $127,066 | $40,618 | 32.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 286 | 297 | $90,730 | $14,695 | 16.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 77 | 79 | $61,085 | $10,947 | 17.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 113 | 132 | $21,894 | $8,360 | 38.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 56 | 60 | $23,079 | $7,451 | 32.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $25,967 | $6,786 | 26.1% |
About Dr. Ryan Miller, M.D
Dr. Ryan Miller, M.D is a Cardiovascular Disease healthcare provider based in Morganton, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740243823.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ryan Miller, M.D has received a total of $1,216 in payments from pharmaceutical and medical device companies, with $41.76 received in 2024. These payments were reported across 76 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($1,216).
As a Medicare-enrolled provider, Miller has provided services to 9,716 Medicare beneficiaries, totaling 12,262 services with total Medicare billing of $451,642. Data is available for 4 years (2020–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Morganton, NC
- Active Since 04/10/2006
- Last Updated 10/08/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1740243823
Products in Payments
- ELIQUIS (Drug) $396.80
- ENTRESTO (Drug) $202.47
- VERQUVO (Drug) $173.12
- JOT DX (Device) $75.98
- LEQVIO (Drug) $71.47
- BRILINTA (Drug) $41.19
- FARXIGA (Drug) $41.11
- PRADAXA (Drug) $27.46
- Hillrom - Carnation Ambulatory Monitor (Device) $26.86
- Corlanor (Drug) $26.41
- XARELTO (Drug) $23.82
- BELSOMRA (Drug) $23.04
- Vascepa (Drug) $16.34
- CHANTIX (Drug) $15.22
- XIFAXAN (Drug) $14.90
- PROMUS EVEROLIMUS-ELUTING CORONARY STENT SYSTEM (Device) $14.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Morganton
Sean Pokorney, Md, MD
Cardiovascular Disease — Payments: $410,394
Cardiovascular Disease $410,394
Dr. Steven Isserman, M.d, M.D
Cardiovascular Disease — Payments: $8,645
Cardiovascular Disease $8,645
Fernando De La Serna, Md, MD
Cardiovascular Disease — Payments: $6,359
Cardiovascular Disease $6,359
Dr. Walter Pearcy, M.d, M.D
Cardiovascular Disease — Payments: $4,663
Cardiovascular Disease $4,663
Dr. Sardar Shah Khan, M.d., M.r.c.p, M.D., M.R.C.P
Cardiovascular Disease — Payments: $198.26
Cardiovascular Disease $198.26
Dr. Charles Vasey, M.d, M.D
Cardiovascular Disease — Payments: $43.51
Cardiovascular Disease $43.51